今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

韩国游客赴华热情高涨！春节假期游客数量暴增九倍

北京 - 随着中国边境政策的逐渐放开，韩国游客赴华热情高涨。据韩国观光发展协会统计，今年春节假期期间，赴华韩国游客数量同比激增900%，达到2019年同期水平的一半以上。这标志着中韩旅游业在经历三年疫情阻隔后迎来强劲复苏。

春节假期期间，韩国游客们主要前往中国海南、北京、上海等热门旅游目的地。他们热衷于体验中华文化，品尝中国美食，感受中国春节的喜庆氛围。海南的温暖阳光和优美海滩、北京的历史文化遗迹和现代化都市风光、上海的繁华商业区和时尚潮流都吸引了众多韩国游客。

韩国游客的激增也为中国旅游业带来了显著的经济效益。据统计，春节假期期间，韩国游客在中国的平均消费额为每人5000元人民币，高于中国国内游客的平均水平。他们的到来为中国餐饮、住宿、交通、购物等行业带来了大量客流和收入。

中韩两国是近邻，两国人民之间有着深厚的友谊。近年来，两国在经贸、文化、旅游等领域交流合作不断加强。随着两国边境政策的放开，中韩旅游业将迎来更大发展空间。预计未来赴华韩国游客数量将继续增长，中韩旅游合作也将更加深入。

专家分析：

韩国游客赴华热情高涨的原因主要有以下几点：

• 中国疫情防控措施取得显著成效，韩国游客赴华更加安心。
• 中国出台了一系列促进旅游消费的政策措施，吸引了更多韩国游客。
• 韩国国内经济形势低迷，赴华旅游性价比更高。
• 中韩两国文化交流密切，韩国民众对中国文化和旅游产品有着浓厚兴趣。

业界展望：

随着中韩两国人员往来更加便利，两国旅游业将迎来更大发展机遇。未来，两国应进一步加强旅游合作，推出更多优质的旅游产品和服务，满足两国游客的个性化需求，推动中韩旅游业迈上更高台阶。